Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model

European Journal of Surgical Oncology

Volumn 29, Issue 9, 2003, Pages 721-730

  Fogar, P ^a   Greco, E ^b   Basso, D ^b   Habeler, W ^c   Navaglia, F ^b   Zambon, C F ^a   Tormen, D ^a   Gallo, N ^b   Cecchetto, A ^a   Plebani, M ^b   Pedrazzoli, Sergio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c Ospedale Busonera   (Italy)

Author keywords

Animal model; HSV TK; Pancreatic cancer; Suicide gene therapy

Indexed keywords

GANCICLOVIR; INTERLEUKIN 2; RETROVIRUS VECTOR; SODIUM CHLORIDE; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; IN VIVO STUDY; LIVER METASTASIS; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SCID MOUSE; SPLEEN CANCER; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

EID: 0344464885     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2003.08.001     Document Type: Article

References (43)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. Cancer J Clin 2000; 50: 7-33.
2. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21: 195-200.
3. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-60.
4. Zhang J, Russell SJ. Vectors for cancer gene therapy. Cancer Metastasis Rev 1996; 15: 385-401.
5. Rigg AS, Scarpa A, Pandha HS, Lemoine NR. Gene therapy for pancreatic cancer. Ital J Gastroenterol Hepatol 1998; 30: 462-6.
6. Rosenberg L. Pancreatic cancer. a review of emerging therapies. Drugs 2000; 59: 1071-89.
7. Danthinne X, Imperiale MJ. Production of first generation adenovirus vectors: a review. Gene Ther 2000; 7: 1707-14.
8. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-87.
9. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type I thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A 1996; 93: 3525-9.
10. Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996; 224: 405-17.
11. Kimura M, Tagawa M, Takenaga K et al. Drug resistance to ganciclovir observed in suicide gene therapy is due to the loss of integrated herpes simplex virus-thymidine kinase gene. Int J Oncol 1997; 10: 775-8.
12. Faulds D, Rennie CH. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 1990; 39: 567-638.
13. Aoki K, Yoshida T, Matsumoto N et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105-13.
14. Grignet-Debrus C, Calberg-Bacq C-M. Potential of varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Ther 1997; 4: 560-9.
15. Block A, Chen SH, Kosai K, Finegold M, Woo SL. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 1997; 15: 25-34.
16. Mizuno M, Yoshida J, Colosi P, Kurtzman G. Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res 1998; 89: 76-80.
17. Hall SJ, Mutchnik S, Yang G et al. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 1999; 6: 54-63.
18. Shalev M, Kadmon D, Teh B et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000; 163: 1747-50.
19. Beck C, Cayeux S, Lupton SD, Dorken B, Blonkenstein T. The thymidine kinase/ganciclovir-mediated 'suicide' effect is variable in different tumor cells. Hum Gene Ther 1995; 6: 1525-30.
20. Yang L, Hwang R, Chiang Y, Gordon EM, Anderson WF, Parekh D. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clin Cancer Res 1998; 4: 731-41.
21. Boucher PD, Ruch RJ, Shewach DS. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther 1998; 9: 801-14.
22. Elshami AA, Saavedra A, Zhang H et al. Gap junction plays a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3: 85-92.
23. Kumar NM, Gilula NB. The gap junction communication channel. Cell 1996; 84: 381-8.
24. Mesnil M, Yamasaki H. Bystander effects in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60: 3989-99.
25. Qiao J, Black ME, Caruso M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000; 11: 1569-76.
26. Carriò M, Mazo A, Lòpez-Iglesias C, Estivill X, Fillat C. Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells. Results in variable efficiency on the bystander killing: implications for gene therapy. Int J Cancer 2001; 94: 81-8.
27. Humphreys MJ, Greenhalf W, Neoptolemos JP, Ghaneh P. The potential for gene therapy in pancreatic cancer. Int J Pancreatol 1999; 26: 5-21.
28. Gilliam AD, Watson SA. Emerging biological therapies for pancreatic carcinoma. EJSO 2002; 28: 370-8.
29. Clary BM, Coveney EC, Philip R et al. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene transduced tumour cells. Cancer Gene Ther 1997; 4: 97-104.
30. Kimura M, Tagawa M, Takenaga K et al. Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: a potentiality for cancer gene therapy. Cancer Lett 1998; 128: 47-53.
31. Kimura M, Yoshida Y, Narita M et al. Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus. Int J Cancer 1999; 82: 549-55.
32. D'Angelica M, Karpoff H, Halterman M et al. In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunol Immunother 1999; 47: 265-71.
33. Pizzato M, Franchin E, Calvi P et al. Production and characterization of a bicistronic Moloney-based retroviral expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. Gene Ther 1998; 5: 1003-7.
34. Carriò M, Romagosa A, Mercade E et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of herpes simplex virus thymidine kinase gene. Gene Ther 1999; 6: 547-53.
35. Evoy D, Hirschowitz EA, Naama Ha et al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 1997; 69: 226-31.
36. Shirakawa T, Gardner TA, Ko S-C et al. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol 1999; 162: 949-54.
37. Erbs P, Regulier E, Kintz J et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-22.
38. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
39. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003; 2: 6.
40. Greco E, Fogar P, Basso D et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect. Pancreas 2002; 25(2): 21-9.
41. Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JDI. An orthotopic in vivo model of human pancreatic cancer. Surgery 1999; 126: 562-7.
42. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.
43. Wakefield LM, Roberts AB. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002; 12: 22-9.